Akorn, Inc. (NASDAQ: AKRX), a niche generic pharmaceutical company, today reported financial results for its third quarter ended September 30, 2013.
Raj Rai, Chief Executive Officer, commented, “We are pleased with our third quarter results as we continue to demonstrate a strong double-digit growth rate in our top-line despite the delays in getting regulatory approvals from the U.S. Food and Drug Administration.
Help employers find you! Check out all the jobs and post your resume.
